data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Kintara Therapeutics
(NASDAQ:KTRA)
0.2915
0.0065[2.28%]
Last update: 2:57PM
15 minutes delayed
Day High/Low0.29 - 0.31
52 Week High/Low0.14 - 2.85
Open / Close0.31 / -
Float / Outstanding65.3M / 65.5M
Vol / Avg.2.1M / 4M
Mkt Cap19.1M
P/E-
50d Avg. Price0.22
Div / Yield-
Payout Ratio-
EPS-0.11
Total Float65.3M

Kintara Therapeutics (NASDAQ:KTRA), Quotes and News Summary

Kintara Therapeutics (NASDAQ: KTRA)

Day High/Low0.29 - 0.31
52 Week High/Low0.14 - 2.85
Open / Close0.31 / -
Float / Outstanding65.3M / 65.5M
Vol / Avg.2.1M / 4M
Mkt Cap19.1M
P/E-
50d Avg. Price0.22
Div / Yield-
Payout Ratio-
EPS-0.11
Total Float65.3M
Benzinga - 3 days ago
Benzinga - Jun 15, 2022, 11:37AM
Benzinga - Jun 15, 2022, 10:45AM
Benzinga - Jun 15, 2022, 9:21AM
Benzinga - Jun 15, 2022, 9:01AM
Benzinga - Jun 3, 2022, 9:01AM
Benzinga - May 27, 2022, 9:32AM
Benzinga - May 16, 2022, 10:00AM
Benzinga - May 13, 2022, 8:11AM
load more
Sector: Health Care.Industry: Biotechnology
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications.
Read More

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2022-09-27
REV
Q3 2022Est.ActualSurprise
EPS-0.110
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Kintara Therapeutics Questions & Answers

Q
How do I buy Kintara Therapeutics (KTRA) stock?
A

You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Kintara Therapeutics's (KTRA) competitors?
Q
What is the target price for Kintara Therapeutics (KTRA) stock?
A

The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Dawson James on Monday, May 16, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Kintara Therapeutics (KTRA)?
A

The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $0.2915 last updated Today at June 27, 2022, 6:57 PM UTC.

Q
Does Kintara Therapeutics (KTRA) pay a dividend?
A

There are no upcoming dividends for Kintara Therapeutics.

Q
When is Kintara Therapeutics (NASDAQ:KTRA) reporting earnings?
A

Kintara Therapeutics’s Q4 earnings are confirmed for Tuesday, September 27, 2022.

Q
Is Kintara Therapeutics (KTRA) going to split?
A

There is no upcoming split for Kintara Therapeutics.

Q
What sector and industry does Kintara Therapeutics (KTRA) operate in?
A

Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.